Oncolytics Biotech Inc. (ONCY)
NASDAQ: ONCY · IEX Real-Time Price · USD
1.055
+0.015 (1.44%)
Apr 23, 2024, 11:32 AM EDT - Market open
Oncolytics Biotech Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Oncolytics Biotech stock have an average target of 5.50, with a low estimate of 3.00 and a high estimate of 9.00. The average target predicts an increase of 421.33% from the current stock price of 1.06.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ONCY stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Raymond James | Raymond James | Buy Initiates $3 | Buy | Initiates | $3 | +184.36% | Apr 4, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 | Strong Buy | Maintains | $5 | +373.93% | Mar 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +373.93% | Feb 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +373.93% | Jan 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +373.93% | Jan 4, 2024 |
Financial Forecast
Revenue This Year
1.52M
Revenue Next Year
10.08M
from 1.52M
Increased by 565.08%
EPS This Year
-0.42
from -0.41
EPS Next Year
-0.46
from -0.42
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 6.3M | 41.9M | 139.3M | 208.8M | 424.7M |
| Avg | 1.5M | 10.1M | 44.7M | 101.7M | 238.4M |
| Low | n/a | n/a | n/a | 5.7M | 44.1M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 2,665.8% | 1,282.5% | 367.5% | 317.5% |
| Avg | - | 565.1% | 343.3% | 127.8% | 134.4% |
| Low | - | - | - | -87.2% | -56.6% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.38 | -0.40 | -0.41 | 1.55 | 2.78 |
| Avg | -0.42 | -0.46 | -0.43 | 1.50 | 2.67 |
| Low | -0.45 | -0.54 | -0.49 | 1.45 | 2.60 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | 86.0% |
| Avg | - | - | - | - | 78.9% |
| Low | - | - | - | - | 73.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.